Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2023-12-10 Epub Date: 2023-10-11 DOI:10.1200/JCO.23.01435

Humera Khurshid, Nofisat Ismaila, Jessica Bian, Raetasha Dabney, Millie Das, Peter Ellis, Jill Feldman, Christine Hann, Swati Kulkarni, Janessa Laskin, Rami Manochakian, Deebya Raj Mishra, Isabel Preeshagul, Pavan Reddy, Ashish Saxena, Frank Weinberg, Gregory P Kalemkerian

{"title":"Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.","authors":"Humera Khurshid, Nofisat Ismaila, Jessica Bian, Raetasha Dabney, Millie Das, Peter Ellis, Jill Feldman, Christine Hann, Swati Kulkarni, Janessa Laskin, Rami Manochakian, Deebya Raj Mishra, Isabel Preeshagul, Pavan Reddy, Ashish Saxena, Frank Weinberg, Gregory P Kalemkerian","doi":"10.1200/JCO.23.01435","DOIUrl":null,"url":null,"abstract":"Purpose: To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer.Methods: An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.Results: The literature search identified 95 relevant studies to inform the evidence base for this guideline.Recommendations: Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance status, role of biomarkers, and use of myeloid-supporting agents in patients with small-cell lung cancer.Additional information is available at www.asco.org/thoracic-cancer-guidelines.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"5448-5472"},"PeriodicalIF":42.1000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO.23.01435","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer.

Methods: An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

Results: The literature search identified 95 relevant studies to inform the evidence base for this guideline.

Recommendations: Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance status, role of biomarkers, and use of myeloid-supporting agents in patients with small-cell lung cancer.Additional information is available at www.asco.org/thoracic-cancer-guidelines.

查看原文本刊更多论文

癌症小细胞肺癌的系统治疗：ASCO-Ontario健康（癌症护理安大略省）指南。

目的：为执业临床医生对小细胞肺癌癌症患者的管理提供循证建议。方法：召集了一个由医学肿瘤学、胸外科、放射肿瘤学、肺部、社区肿瘤学、研究方法和倡导专家组成的专家小组进行文献检索，其中包括1990年至2022年发表的系统综述、荟萃分析和随机对照试验。感兴趣的结果包括有效率、总生存率、无病生存率或无复发生存率和生活质量。专家小组成员利用现有证据和非正式协商一致意见制定了循证指南建议。结果：文献检索确定了95项相关研究，为本指南提供了证据基础。建议：制定了基于证据的建议，以解决小细胞肺癌癌症患者的全身治疗选择、治疗时机、年龄较大或表现不佳患者的治疗、生物标志物的作用以及骨髓支持剂的使用。有关更多信息，请访问www.asco.org/thoracic-cancer-guidelines。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.